Tu Q S, Ye S D
Department of Cardiovascular Surgery, Affiliated Hospital, Hainan Medical College, Haikou.
J Tongji Med Univ. 1995;15(1):50-4. doi: 10.1007/BF02887886.
This study aimed at the exploration of the relationship between Na(+)-H+ exchange system and myocardial ischemia-reperfusion injury (MRI) in an attempt to provide a theoretic basis for the prevention and treatment of MRI. We used the isolated working guinea pig hearts as the experimental model to mimick cardiopulmonary bypass, which included 120 min hypothermic ischemic cardioplegic arrest followed by 60 min normothermic reperfusion. The hearts were divided into 2 groups: the control group receiving St. Thomas' Hospital Solution (STS) and the treated group receiving STS + amiloride, a Na(+)-H+ exchange blocker. The results showed that during reperfusion, [Na+]i and [Ca2+]i overloads, poor recovery of cardiac function, increases in CPK release and OFR generation, reduction of ATP content and serious damage of ultrastructure were seen in group 1; whereas there were no [Na+]i and [Ca2+]i overloads and better recovery of cardiac function accompanied by improved results of biochemical assay and less damage of ultrastructure was found in group 2. Our study indicates that amiloride can inhibit Na(+)-H+ exchange system in cardiac cells during early reperfusion period, which prevents [Na+]i overload produced by Na(+)-H+ exchange, and stops Na(+)-Ca2+ exchange activated by high level of [Na+]i, thus attenuating [Ca2+]i overload caused by Na(+)-Ca2+ exchange and myocardial injury. Therefore, we conclude that Na(+)-H+ exchange blocker, amiloride, can exert significant protective effects on MRI and its use may prove to be a new clinical approach to prevention and cure of MRI.
本研究旨在探讨钠氢交换系统与心肌缺血再灌注损伤(MRI)之间的关系,以期为MRI的防治提供理论依据。我们采用离体工作的豚鼠心脏作为实验模型来模拟体外循环,包括120分钟低温缺血性心脏停搏,随后60分钟常温再灌注。心脏被分为2组:对照组接受圣托马斯医院溶液(STS),治疗组接受STS + 氨氯吡脒(一种钠氢交换阻滞剂)。结果显示,再灌注期间,第1组可见细胞内钠([Na+]i)和细胞内钙([Ca2+]i)超载、心功能恢复差、肌酸磷酸激酶(CPK)释放增加、氧自由基(OFR)生成增加、三磷酸腺苷(ATP)含量降低以及超微结构严重损伤;而第2组未见[Na+]i和[Ca2+]i超载,心功能恢复较好,生化检测结果改善,超微结构损伤较轻。我们的研究表明,氨氯吡脒可在再灌注早期抑制心肌细胞中的钠氢交换系统,防止因钠氢交换产生的[Na+]i超载,并阻止由高水平[Na+]i激活的钠钙交换,从而减轻因钠钙交换引起的[Ca2+]i超载和心肌损伤。因此,我们得出结论,钠氢交换阻滞剂氨氯吡脒对MRI可发挥显著的保护作用,其应用可能成为防治MRI的一种新的临床方法。